Prediction of Rivaroxaban-Rifampin Interaction After Major Orthopedic Surgery: Physiologically Based Pharmacokinetic Modeling and Simulation
Rivaroxaban is commonly used for the prophylaxis of venous thromboembolism (VTE) for patients undergoing major orthopedic surgery. Rivaroxaban is primarily eliminated by hepatic CYP450 metabolism and renal excretion. Rifampin is a commonly used antibiotic for prosthetic joint infections (PJI) and a...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-07-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2021.706781/full |
id |
doaj-946e3def448a44179f3e7c4613c556b0 |
---|---|
record_format |
Article |
spelling |
doaj-946e3def448a44179f3e7c4613c556b02021-07-23T07:53:58ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122021-07-011210.3389/fphar.2021.706781706781Prediction of Rivaroxaban-Rifampin Interaction After Major Orthopedic Surgery: Physiologically Based Pharmacokinetic Modeling and SimulationRui-juan Xu0Rui-juan Xu1Tao Ling2Hong Tang3Wei-hong Ge4Qing Jiang5Department of Pharmacy, Drum Tower Hospital Affiliated to Medical School of Nanjing University, Nanjing, ChinaDepartment of Sports Medicine and Adult Reconstructive Surgery, Drum Tower Hospital Affiliated to Medical School of Nanjing University, Nanjing, ChinaSchool of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, ChinaDepartment of Analysis, Nanjing GQ Laboratories co., Ltd, Nanjing, ChinaDepartment of Pharmacy, Drum Tower Hospital Affiliated to Medical School of Nanjing University, Nanjing, ChinaDepartment of Sports Medicine and Adult Reconstructive Surgery, Drum Tower Hospital Affiliated to Medical School of Nanjing University, Nanjing, ChinaRivaroxaban is commonly used for the prophylaxis of venous thromboembolism (VTE) for patients undergoing major orthopedic surgery. Rivaroxaban is primarily eliminated by hepatic CYP450 metabolism and renal excretion. Rifampin is a commonly used antibiotic for prosthetic joint infections (PJI) and a potent inducer of CYP450 enzymes. Clinical data about drug-drug interactions of rivaroxaban and rifampin are limited. The present study is to describe DDI of rivaroxaban and rifampin in several prosthetic joint infections patients undergoing major orthopedic surgery. We retrospectively identified six patients concomitantly administered with rivaroxaban and rifampin between 2019 and 2020. Plasma samples of these patients with accurate sampling time were chosen from the biobank and plasma levels of rivaroxaban were measured at each time point. A physiologically based pharmacokinetic model for the rivaroxaban-rifampin interaction was developed to predict the optimal dosing regimen of rivaroxaban in the case of co-medication with rifampin. The model was validated by the observed plasma concentration of rivaroxaban from the above patients. From this model, it could be simulated that when rifampin starts or stops, gradually changing rivaroxaban dose during the first few days would elevate the efficacy and safety of rivaroxaban.https://www.frontiersin.org/articles/10.3389/fphar.2021.706781/fullphysiologically based pharmacokineticdrug drug interactionrivaroxabanrifampinprosthetic joint infection |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Rui-juan Xu Rui-juan Xu Tao Ling Hong Tang Wei-hong Ge Qing Jiang |
spellingShingle |
Rui-juan Xu Rui-juan Xu Tao Ling Hong Tang Wei-hong Ge Qing Jiang Prediction of Rivaroxaban-Rifampin Interaction After Major Orthopedic Surgery: Physiologically Based Pharmacokinetic Modeling and Simulation Frontiers in Pharmacology physiologically based pharmacokinetic drug drug interaction rivaroxaban rifampin prosthetic joint infection |
author_facet |
Rui-juan Xu Rui-juan Xu Tao Ling Hong Tang Wei-hong Ge Qing Jiang |
author_sort |
Rui-juan Xu |
title |
Prediction of Rivaroxaban-Rifampin Interaction After Major Orthopedic Surgery: Physiologically Based Pharmacokinetic Modeling and Simulation |
title_short |
Prediction of Rivaroxaban-Rifampin Interaction After Major Orthopedic Surgery: Physiologically Based Pharmacokinetic Modeling and Simulation |
title_full |
Prediction of Rivaroxaban-Rifampin Interaction After Major Orthopedic Surgery: Physiologically Based Pharmacokinetic Modeling and Simulation |
title_fullStr |
Prediction of Rivaroxaban-Rifampin Interaction After Major Orthopedic Surgery: Physiologically Based Pharmacokinetic Modeling and Simulation |
title_full_unstemmed |
Prediction of Rivaroxaban-Rifampin Interaction After Major Orthopedic Surgery: Physiologically Based Pharmacokinetic Modeling and Simulation |
title_sort |
prediction of rivaroxaban-rifampin interaction after major orthopedic surgery: physiologically based pharmacokinetic modeling and simulation |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Pharmacology |
issn |
1663-9812 |
publishDate |
2021-07-01 |
description |
Rivaroxaban is commonly used for the prophylaxis of venous thromboembolism (VTE) for patients undergoing major orthopedic surgery. Rivaroxaban is primarily eliminated by hepatic CYP450 metabolism and renal excretion. Rifampin is a commonly used antibiotic for prosthetic joint infections (PJI) and a potent inducer of CYP450 enzymes. Clinical data about drug-drug interactions of rivaroxaban and rifampin are limited. The present study is to describe DDI of rivaroxaban and rifampin in several prosthetic joint infections patients undergoing major orthopedic surgery. We retrospectively identified six patients concomitantly administered with rivaroxaban and rifampin between 2019 and 2020. Plasma samples of these patients with accurate sampling time were chosen from the biobank and plasma levels of rivaroxaban were measured at each time point. A physiologically based pharmacokinetic model for the rivaroxaban-rifampin interaction was developed to predict the optimal dosing regimen of rivaroxaban in the case of co-medication with rifampin. The model was validated by the observed plasma concentration of rivaroxaban from the above patients. From this model, it could be simulated that when rifampin starts or stops, gradually changing rivaroxaban dose during the first few days would elevate the efficacy and safety of rivaroxaban. |
topic |
physiologically based pharmacokinetic drug drug interaction rivaroxaban rifampin prosthetic joint infection |
url |
https://www.frontiersin.org/articles/10.3389/fphar.2021.706781/full |
work_keys_str_mv |
AT ruijuanxu predictionofrivaroxabanrifampininteractionaftermajororthopedicsurgeryphysiologicallybasedpharmacokineticmodelingandsimulation AT ruijuanxu predictionofrivaroxabanrifampininteractionaftermajororthopedicsurgeryphysiologicallybasedpharmacokineticmodelingandsimulation AT taoling predictionofrivaroxabanrifampininteractionaftermajororthopedicsurgeryphysiologicallybasedpharmacokineticmodelingandsimulation AT hongtang predictionofrivaroxabanrifampininteractionaftermajororthopedicsurgeryphysiologicallybasedpharmacokineticmodelingandsimulation AT weihongge predictionofrivaroxabanrifampininteractionaftermajororthopedicsurgeryphysiologicallybasedpharmacokineticmodelingandsimulation AT qingjiang predictionofrivaroxabanrifampininteractionaftermajororthopedicsurgeryphysiologicallybasedpharmacokineticmodelingandsimulation |
_version_ |
1721290400212189184 |